About Aethlon Medical
Aethlon Medical (NASDAQ:AEMD) focuses on developing unique treatments for life-threatening diseases that lack effective therapies. Specializing in the development of medical devices, Aethlon Medical is best known for its pioneering work on the Hemopurifier®, a device designed to reduce the presence of infectious viruses and cancer-promoting exosomes in the blood. The goal of the company is to address critical unmet needs in global health, including severe viral diseases and cancer, by advancing these novel therapeutic products through clinical trials and eventually to the market, potentially benefiting patients worldwide who currently have limited options. Aethlon Medical is dedicated to innovation in the field of biofiltration and continues to explore the potential applications of its technologies in various medical conditions.
Snapshot
Operations
Products and/or services of Aethlon Medical
- The Hemopurifier, a device designed for the removal of viruses and cancer-promoting exosomes from blood.
- Research on the potential use of Hemopurifier for treating severe COVID-19 cases by removing SARS-CoV-2 viruses.
- Development of therapeutic approaches for cancer, focusing on the removal of circulating tumor-derived exosomes that can promote cancer progression.
- Initiatives in infectious disease treatment, targeting the clearance of viral pathogens for patients with life-threatening conditions.
- Collaboration with government and military entities to develop treatments for bioterrorism threats, including filtering bloodborne pathogens.
- Exploratory research in chronic conditions, aimed at studying the Hemopurifier's efficacy in diseases such as Chronic Kidney Disease (CKD).
Aethlon Medical executive team
- Mr. James B. Frakes M.B.A.CEO, CFO, Chief Accounting Officer, Secretary & Director
- Dr. Steven P. LaRosa M.D.Chief Medical Officer
- Ms. Michele BombardiereVP & Controller